We hypothesized that the dramatic suppression of TNFα with clenbuterol treatment might be down-regulating the overall brain immune response to stroke at this sub-acute time point, so we also measured mRNA levels of another key pro-inflammatory mediator (iNOS) and an anti-inflammatory molecule (Ym1). The gene discussed is TNF; the disease is stroke disorder.